MiDeTe - microRNA Levels Under Denosumab and Teriparatide Therapy in Postmenopausal Osteoporosis

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 1, 2017

Primary Completion Date

September 1, 2022

Study Completion Date

September 30, 2022

Conditions

Postmenopausal OsteoporosisDiabetes Type 2

Interventions

DRUG

Prolia, 60 Mg/mL Subcutaneous Solution

antiresorptive treatment with Prolia

DRUG

Teriparatide

osteoanabolic treatment with Forsteo

Trial Locations (1)

Medical University Vienna; St. Vincent Hospital, Vienna

All Listed Sponsors

collaborator

St. Vincent Hospital, Vienna

OTHER

lead

Medical University of Vienna

OTHER

NCT03472846 - MiDeTe - microRNA Levels Under Denosumab and Teriparatide Therapy in Postmenopausal Osteoporosis | Biotech Hunter | Biotech Hunter